Please provide your email address to receive an email when new articles are posted on . Through an evolution that has seen several prototypes enter and leave the scene, ultra-small drainage devices ...

A tiny medical device no larger than an eyelash may significantly reduce eye pressure in glaucoma patients and allow some to stop using eye-drop medications, according to year-one clinical trial ...

Ivantis is the maker of the Hydrus Microstent, an eyelash-sized device that was approved by the FDA in 2018 to treat glaucoma in minimally invasive cataract surgeries. (Bruno Henrique/Pixabay) () ...

Alcon is getting a second shot at competing in the minimally invasive glaucoma surgery (MIGS) market. The Geneva, Switzerland-based company has announced its intention to acquire Ivantis, the ...

The competition in the microinvasive glaucoma surgical (MIGS) space is certainly heating up after today’s news. FDA has given a nod to Ivantis’ Hydrus Microstent, which will undoubtedly compete ...

CORONADO, California — In glaucoma patients, the implantation of an intracanalicular microstent (Hydrus, Ivantis) maintains low intraocular pressure for 2 years and reduces the need for medication, a ...

CHICAGO -- For the first time in a multicenter randomized trial, minimally invasive glaucoma surgery (MIGS) with an intracanalicular (Schlemm's canal) stent significantly reduced long-term vision loss ...

Other implants, namely the Hydrus Microstent (Ivantis) and the first- and second-generation iStent trabecular micro-bypass (Glaukos) target the Schlemm’s canal, while the third-generation iStent and ...

CHICAGO, IL--(Marketwire - Nov 13, 2012) - A tiny medical device no larger than an eyelash may significantly reduce eye pressure in glaucoma patients and allow some to stop using eye-drop medications, ...

Thomas W. Samuelson, M.D., glaucoma specialist with Minnesota Eye Consultants, served as the HYDRUS I trial's medical monitor Click here for high-resolution version The Hydrus stent is one of several ...